Ahmed Alanazi/X
May 31, 2025, 06:42
Ahmed Alanazi Shared BREAKWATER Trial Results in BRAF-Mutated mCRC at ASCO 2025
Ahmed Alanazi, Department Program Director at King Fahad Medical City, shared a post on X:
“BREAKWATER: In mCRC with BRAFV600E EC+mFOLFOX6 has shown:
– reduced the death by 51%
– longer duration on therapy vs SOC
– Median PFS 12.8 vs 7.1 months HR:0.55 (CI 0.407-0.677) P < 0.0001
– Median OS 30.3 vs 15.1 months HR:0.49 (CI 0.375-0.632) P <0.0001.”
More posts featuring ASCO25.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 31, 2025, 06:42
May 31, 2025, 05:11
May 31, 2025, 05:08
May 31, 2025, 05:02
May 31, 2025, 04:50
May 31, 2025, 04:43
May 31, 2025, 04:30